Home/Filings/4/0000950170-24-037397
4//SEC Filing

GRAYZEL DAVID S. 4

Accession 0000950170-24-037397

CIK 0001661998other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 5:39 PM ET

Size

5.9 KB

Accession

0000950170-24-037397

Insider Transaction Report

Form 4
Period: 2024-03-25
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-03-25+12,76712,767 total
    Exercise: $16.82Exp: 2034-03-24Common Stock (12,767 underlying)
Footnotes (2)
  • [F1]One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
  • [F2]This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Documents

1 file

Issuer

Q32 Bio Inc.

CIK 0001661998

Entity typeother

Related Parties

1
  • filerCIK 0001732786

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 5:39 PM ET
Size
5.9 KB